Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance-Reference-Cited by-同舟云学术

Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance

Published:2017-03 Issue:379 Volume:9 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Roh Whijae¹²^ORCID,Chen Pei-Ling¹³^ORCID,Reuben Alexandre⁴^ORCID,Spencer Christine N.¹^ORCID,Prieto Peter A.⁴,Miller John P.⁵^ORCID,Gopalakrishnan Vancheswaran⁴^ORCID,Wang Feng¹,Cooper Zachary A.¹⁴^ORCID,Reddy Sangeetha M.⁶,Gumbs Curtis¹^ORCID,Little Latasha¹^ORCID,Chang Qing¹,Chen Wei-Shen¹³^ORCID,Wani Khalida⁷,De Macedo Mariana Petaccia⁷⁸,Chen Eveline⁷^ORCID,Austin-Breneman Jacob L.⁴^ORCID,Jiang Hong⁴,Roszik Jason¹⁹^ORCID,Tetzlaff Michael T.³^ORCID,Davies Michael A.⁹,Gershenwald Jeffrey E.⁴^ORCID,Tawbi Hussein⁹^ORCID,Lazar Alexander J.⁴⁷^ORCID,Hwu Patrick⁹^ORCID,Hwu Wen-Jen⁹^ORCID,Diab Adi⁹^ORCID,Glitza Isabella C.⁹^ORCID,Patel Sapna P.⁹,Woodman Scott E.⁹,Amaria Rodabe N.⁹,Prieto Victor G.³^ORCID,Hu Jianhua¹⁰,Sharma Padmanee¹¹¹²,Allison James P.¹¹,Chin Lynda¹³,Zhang Jianhua¹⁴,Wargo Jennifer A.¹⁴^ORCID,Futreal P. Andrew¹^ORCID

Affiliation:

1. Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

2. Cancer Biology Graduate Program, The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences at Houston, Houston, TX 77030, USA.

3. Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

4. Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

5. Oncology Research for Biologics and Immunotherapy Translation, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

6. Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

7. Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

8. Pathology Department, A.C.Camargo Cancer Center, São Paulo, SP-01509-010, Brazil.

9. Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

10. Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

11. Department of Immunology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

12. Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

13. University of Texas System, Austin, TX 78701, USA.

14. Applied Cancer Science Institute, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

Abstract

Profiling of melanoma patients treated with checkpoint blockade reveals TCR clonality and copy number loss as correlates of therapeutic response.

Funder

National Institutes of Health

National Cancer Institute

Welch Foundation

Cancer Prevention and Research Institute of Texas

Melanoma Research Alliance

Dr. Miriam and Sheldon G. Adelson Medical Research Foundation

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference71 articles.

1. Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

2. Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

3. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

4. Nivolumab plus Ipilimumab in Advanced Melanoma

5. Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma

Cited by 609 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. TNF and IFNγ-induced cell death requires IRF1 and ELAVL1 to promote CASP8 expression;Journal of Cell Biology;2024-02-06

2. Tumor-infiltrating lymphocytes as a prognostic and predictive factor for Melanoma;Expert Review of Molecular Diagnostics;2024-02-05

3. Construction of a prognostic model for lung adenocarcinoma tumor endothelial cells and prediction of immunotherapy based on single-cell transcriptome and Bulk transcriptome;2024-02-02

4. Deciphering the immune modulation through deep transcriptomic profiling and therapeutic implications of DNA damage repair pattern in hepatocellular carcinoma;Cancer Letters;2024-02

5. Characterization of T cell receptor repertoire in penile cancer;Cancer Immunology, Immunotherapy;2024-01-27